Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis

San Diego, CA, December 4, 1998 -- Signal Pharmaceuticals today announced the successful completion of preclinical studies demonstrating the ability of two series of compounds to safely and effectively inhibit bone resorption in animal models of osteoporosis. The drug leads belong to a new class of small molecule compounds termed selective estrogen receptor modulators (SERMs), also referred to as 'designer estrogens.' SERMs are designed to mimic the positive effects of estrogen by inhibiting bone loss in postmenopausal women, while avoiding some of estrogen's adverse effects such as increased risk of breast and uterine cancer. Moreover, studies have demonstrated that some SERMs, such as Zeneca's tamoxifen (NolvadexTM) and Eli Lilly's raloxifene (EvistaTM), also have anti-estrogenic effects and therefore can be effective in preventing and treating breast cancer. Signal researchers are presenting data from successful preclinical studies at the joint meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society being held in San Francisco, California, December 1-6.

Signal evaluated the efficacy of its novel SERMs in a rodent model of post-menopausal osteoporosis. Left untreated, these animals lose bone mass and eventually develop advanced stages of osteoporosis due to the loss of estrogen function. In the study, two series of drug leads were tested in parallel with estrogen and raloxifene for their ability to inhibit bone resorption. The study concluded that Signal's drug leads were twice as effective as raloxifene in preventing bone loss, at doses equal or less than raloxifene's therapeutic dose. In a separate study, these compounds also demonstrated superior safety, when compared with raloxifene, tamoxifen and estrogen, with regard to potential cancer risks in reproductive tissues. These drugs, if successfully developed, would provide clinicians with an alternative, non-estrogen treatment for osteoporosis

Contact: Neil Cohen
415-677-4455 x205
Noonan/Russo Communications

Page: 1 2 3 4

Related medicine news :

1. Signal identified that enables malarial parasites to target blood cells
2. Signaling pathway may be key to understanding roots of hypertension
3. Mouse study: Signal overload in Alzheimer brains
4. Neurobiologists Show How The Brain Processes Signals From Pheromones
5. Psychiatric Symptoms May Signal Brain Damage From Diet Pills
6. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
7. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
8. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
9. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
10. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
11. Pharmaceuticals and personal care products

Post Your Comments:

(Date:8/11/2018)... ... ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch Dental® in ... to deliver dental care in impoverished communities. Along with a team of fellow ... to help deliver care to over 550 individuals in need. , This outreach was ...
(Date:8/11/2018)... ATLANTA (PRWEB) , ... August 11, 2018 , ... ... winner of a Silver Stevie® Award in the Executive of the Year-Business category ... the world’s premier business awards program. All individuals and organizations worldwide – public ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... by simplifying medication adherence monitoring with Smart-pill bottle and mobile applications, DoseSmart ... the App Orchard. , The DoseSmart medication management and medication adherence platform ...
(Date:8/7/2018)... ... August 07, 2018 , ... Sussex Vision Center, a multi-site optometry practice ... Sussex, OD, founded the practice in Coldwater, and over the last three decades has ... to offer comprehensive eye health services for patients of all ages. , “I ...
(Date:8/3/2018)... ... August 03, 2018 , ... On August 2, 2018 ... proceedings. Mark Sadaka of Sadaka Associates, LLC has been litigating Zostavax injuries ... before the Judicial Panel on Multidistrict Litigation for the thousands of people injured by ...
Breaking Medicine News(10 mins):
(Date:8/3/2018)... ... August 03, 2018 , ... Flexefits, a pioneer in direct -pay, direct access ... allowing participants in Direct Primary Care arrangements to keep HSA eligibility and permit DPC ... individual and $300 per family per month.) , “We are very pleased to see ...
(Date:8/2/2018)... ... ... UMD Professor Utpal Pal leads a team of investigators across multiple institutions ... of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), ... contribute to the spread of major diseases like Lyme disease. Pal is the project ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... with customer relationship management (CRM), patient experience and provider communication solutions for ... Program for Health Information Service Providers (HISPs). DirectTrust is a ...
Breaking Medicine Technology:
Cached News: